The District Court of Rome in Italy has denied a request from Pronova BioPharma to enjoin an Italian company from allegedly infringing its Italian patent for the active pharmaceutical ingredient (API) in its lead product, Omacor/Lovaza. But Pronova said the ruling will not have any impact on its business. This is because of the strong, global sales of its product.
